Celebrex (Celecoxib) Antitrust Class Action Settlement

Berger Montague served as class counsel and obtained a $94 million settlement for the class of direct purchasers of brand and generic Celebrex (celecoxib) in this antitrust action against Pfizer. The plaintiffs alleged that Pfizer, in violation of the Sherman Act, improperly obtained a patent for Celebrex from the U.S. Patent and Trademark Office in a scheme to unlawfully extend patent protection and delay market entry of generic versions of Celebrex. Led by Executive Shareholder David F. Sorensen, the plaintiffs alleged in the United States District Court for the Eastern District of Virginia that Pfizer’s conduct caused the class overcharge damages.

After more than three years of litigation and on the eve of trial, the direct purchaser class settled with Pfizer in the amount of $94 million.

If you or your company has been harmed by anticompetitive conduct or any conduct that you believe violates the antitrust laws, please contact Berger Montague.

About Berger Montague

Berger Montague is a national law firm focusing on complex civil litigation in federal and state courts throughout the United States. For over half a century, Berger Montague has played lead roles in consequential, precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago, Minneapolis, San Diego, San Francisco, Toronto, and Washington, D.C.